NEW YORK – Inocras and Watchmaker Genomics said on Tuesday that they have expanded a partnership for whole-genome sequencing assay development and analysis.
Financial details of the deal were not disclosed.
As part of the collaboration, Inocras adopted Watchmaker’s DNA library prep kits with fragmentation for its CancerVision assay, a target-enhanced whole-genome sequencing test for solid tumors.
"We’re proud to demonstrate the power of whole-genome sequencing and analytics through our diagnostics products," Stephanie Ferguson, Inocras chief clinical operations officer, said in a statement. "Our collaboration with Watchmaker has been important in driving this innovation, and we are excited to continue our partnership on upcoming laboratory-developed assays."
Formerly called Genome Insight, San Diego-based Inocras is a spinout from the Korea Advanced Institute of Science and Technology (KAIST), which is developing whole-genome sequencing assays as well as data curation pipelines for cancer and rare diseases.